# GDNF Gene Therapy for Parkinson's Disease

> **NCT04167540** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Brain Neurotherapy Bio, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **BIOLOGICAL:** AAV2-GDNF

## Key facts

- **NCT ID:** NCT04167540
- **Lead sponsor:** Brain Neurotherapy Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-04-01
- **Primary completion:** 2023-10-17
- **Final completion:** 2027-06
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167540, "GDNF Gene Therapy for Parkinson's Disease". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04167540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*